the aim of this study was to determine the effect of lovastatin and fluvastatin compared with placebo in patients with high levels of total cholesterol and low density lipoprotein cholesterol (ldl - cj on plasma lipid profile. in a prospective single blind clinical trial with convenient sampling 120 hypercholesterolemia men and women with total cholesterol > 220 mg/dl, ldl - c > 160 mgidl, trig...

In this study, the effect of lovastatin and fluvastatin was compared with placebo in patients with high levels of total cholesterol and low density lipoprotein cholesterol (LDL-C) on the plasma lipid profile. In a prospective single blind clinical trial with convenient sampling, 120 hypercholesterolemic men and women with Tcholesterol ≥220 mg/dL, LDL-C ≥ 160 mg/dL, and triglyceride ≤ 350 mg...

AIMS High plasma cholesterol concentration and increased platelet activity are two major risk factors for atherosclerosis. Lovastatin, the lipophilic drug was shown to inhibit platelet aggregation whereas pravastatin, the hydrophilic drug had no such effect. Analysis of the effect of fluvastatin which is both a lipophilic and hydrophilic drug, on platelet aggregation was the goal of the present...

in this study, the effect of lovastatin and fluvastatin was compared with placebo in patients with high levels of total cholesterol and low density lipoprotein cholesterol (ldl-c) on the plasma lipid profile. in a prospective single blind clinical trial with convenient sampling, 120 hypercholesterolemic men and women with tcholesterol ≥220 mg/dl, ldl-c ≥ 160 mg/dl, and triglyceride ≤ 350 mg/dl ...

Four drugs that act as specific inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase--lovastatin, pravastatin, simvastatin, and, most recently, fluvastatin--have been approved by regulatory authorities throughout the world. In the present review, we have critically assessed the comparative hypocholesterolemic effects of these four drugs based on direct comparative studies, wh...

Statins were derived from Penicillium citrinium in 1976 by Endo and his colleagues. Brown et al7 showed that they act by inhibiting HMG-CoA reductase. The first studied statin was compactin which was renamed mevastatin. Lovastatin became the first statin to be approved for human use. Pravastatin and simvastatin are chemically modified derivatives of lovastatin. Atorvastatin, fluvastatin and cer...

3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors prevent the conversion of HMG-CoA to mevalonate and thereby inhibit the synthesis of other products derived from this metabolite. This includes a number of small prenylated GTPases involved in cell growth, motility, and invasion. We studied the effect of HMG-CoA reductase inhibitors (fluvastatin and lovastatin) on in vitro inv...

3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors prevent the conversion of HMG-CoA to mevalonate and thereby inhibit the synthesis of other products derived from this metabolite. This includes a number of small prenylated GTPases involved in cell growth, motility, and invasion. We studied the effect of HMG-CoA reductase inhibitors (fluvastatin and lovastatin) on in vitro inv...

BACKGROUND Cholesterol management drugs known as statins are widely used and often well tolerated; however, a variety of muscle-related side effects can arise. These adverse events (AEs) can have serious impact, and form a significant barrier to therapy adherence. Surveillance of post-marketing AEs is of vital importance to understand real-world AEs and reporting differences between individual ...

Cholesterol is an organic compound, which is produced in humans by a complex metabolism. It acts as a precursor for the synthesis of many steroids, vitamin D and also helps in membrane transport. Increase of cholesterol in humans, leads to Cardio Vascular Disorders and finally death. This can be reduced by inhibiting the HMG-CoA reductase, which is an important precursor in formation of mevolan...